The confluence of demographics, technology, and unmet need is creating a once-in-a-generation opportunity.
If you want to find a sector where the fundamentals are almost impossible to argue with, look at healthcare in emerging markets. I've been investing at the intersection of healthcare and developing economies for years now, and I've never seen the setup look quite like this.
The numbers tell a compelling story on their own. The global middle class is expanding fastest in Southeast Asia, sub-Saharan Africa, and Latin America. As incomes rise, healthcare spending rises with them — historically, it's one of the most reliable relationships in economics. But the story goes well beyond GDP per capita.
Demographics don't lie
The developing world is aging — not as fast as Japan or Germany, but aging nonetheless. India alone will add more people over 65 in the next decade than the entire current population of Australia. Nigeria's urban population is projected to grow by 100 million people by 2050. These are people who will need hospitals, diagnostics, medications, and insurance products that largely don't exist at scale today.
That's not a risk. That's a structural demand driver that no policy, no recession, and no geopolitical event can meaningfully slow over a multi-decade horizon.
Technology is the great equalizer
What's different now versus even a decade ago is mobile infrastructure. Many emerging markets have effectively leapfrogged desktop computing and gone straight to smartphones — and that changes healthcare delivery fundamentally. Telemedicine, digital health records, AI-assisted diagnostics: these aren't futuristic concepts in Lagos or Jakarta. They're active businesses solving real problems right now.
"The best investments I've ever encountered are the ones where the tailwind is so strong that even mediocre execution leads to good outcomes. Healthcare in emerging markets is one of those tailwinds."
The valuation gap is real
From a pure investment perspective, you're often looking at companies delivering 20–30% revenue growth at valuations that would seem absurd if those same businesses were headquartered in Manhattan. Part of that is legitimate — emerging market risk is real, currency volatility is real, regulatory unpredictability is real. But much of it is simply perception lag. Institutional capital is slow to move, and when it does, prices adjust quickly.
At our fund, we spend a significant portion of our time stress-testing exactly these risks. Political regime changes, currency devaluation scenarios, supply chain fragility — all of it goes into the model. But once you've done that work rigorously, what often remains is a genuinely mispriced asset.
The bottom line
I'm not saying emerging market healthcare is without risk. It absolutely is not. But the combination of structural demand, technological enablement, and valuation opportunity makes this, in my view, one of the most interesting places to be deploying capital in the next decade. The investors who do the hard work of understanding these markets today will look very smart in ten years.